Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
University of California, San Francisco
OHSU Knight Cancer Institute
University Hospital, Ghent
Hoffmann-La Roche
Gossamer Bio Inc.
CSPC Ouyi Pharmaceutical Co., Ltd.
Memorial Sloan Kettering Cancer Center
Columbia University
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
EpiAxis Therapeutics
Celgene
The Methodist Hospital Research Institute
University of Chicago
Incyte Corporation
University of Utah
University of California, San Francisco
Celgene Corporation